The Journal of Practical Medicine >
Effect of minimally invasive interventional therapy combined with recombinant tissue plasminogen activator on patients with massive pulmonary embolism
Received date: 2025-09-17
Online published: 2026-02-25
Objective To investigate the impact of minimally invasive intervention combined with rt-PA on survival rates in patients with massive pulmonary embolism (MPE). Methods Retrospectively, patients who received minimally invasive interventional combined rt-PA treatment in our hospital from October 2021 to October 2024 were included in the study group (103 cases), and propensity score matching (PSM) scoring method was used to match patients who received Nadroparin calcium and rt-PA treatment in our hospital during the same period into the control group (97 cases). Comparisons were made between the two groups regarding overall clinical efficacy, 30-day and 90-day post-treatment survival rates, vital signs [heart rate (HR), respiratory rate], blood gas parameters [arterial oxygen partial pressure (PaO2), carbon dioxide partial pressure (PaCO?), pulmonary artery pressure (PAP), and peripheral oxygen saturation (SpO?)], coagulation and fibrinolysis system markers [D-dimer (D-D), plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (t - PA), thrombomodulin (TM), and antithrombin Ⅲ (AT-Ⅲ)], Blood flow dynamics index and total adverse reaction rates. Results After treatment, the overall efficacy rate in the study group was 95.15%, significantly higher than the control group′s 81.44% (P < 0.05). At 30 days post-treatment, there was no significant difference in survival rates between the two groups (P > 0.05). At 90 days post-treatment, the survival rate in the study group was 94.13%, significantly higher than that in the control group (85.57%, P < 0.05). Pretreatment HR and respiratory rate showed no significant differences between the two groups (P > 0.05); post - treatment, both groups exhibited significant reductions in these parameters, with the study group demonstrating lower values than the control group (P < 0.05). Pretreatment PaO?, PaCO?, PAP, and SpO? showed no significant differences (P > 0.05); post-treatment, PaO?, PaCO?, and SpO? significantly increased in both groups, with the study group outperforming the control group (P < 0.05), while PAP significantly decreased, with the study group showing lower values than the control group (P < 0.05). Before treatment, there was no significant difference between the two groups in D - D, PAI-1, t-PA, TM and AT-Ⅲ (P > 0.05). After treatment, D-D, PAI-1, t-PA and TM showed a significant downward trend in both groups, and the study group was significantly lower than the control group; AT-Ⅲ showed an upward trend, and the study group was higher than the control group (P < 0.05). Before treatment, there was no significant difference in RV/LV ratio, sPAP and TAPSE between the two groups (P > 0.05); after treatment, RV/LV ratio and sPAP decreased significantly, while TAPSE increased significantly (P < 0.001), and the decrease of RV/LV ratio and sPAP and increase of TAPSE in the study group were better than those in the control group (P < 0.05). There was no statistical difference in the incidence of overall bleeding events between the two groups (25.77% vs. 16.67%, P > 0.05), However, according to the BARC classification criteria, the incidence of hemorrhagic events of type 3 or higher was higher in the control group than in the study group. Conclusion Minimally invasive intervention combined with rt-PA effectively improves oxygenation, regulates coagulation-fibrinolysis balance, and enhances clinical efficacy in patients with massive pulmonary embolism.
Zongjiang YANG , Xiangyang SHU . Effect of minimally invasive interventional therapy combined with recombinant tissue plasminogen activator on patients with massive pulmonary embolism[J]. The Journal of Practical Medicine, 2026 , 42(4) : 639 -645 . DOI: 10.3969/j.issn.1006-5725.2026.04.014
| [1] | TROTT T, BOWMAN J. Diagnosis and Management of Pulmonary Embolism [J]. Emerg Med Clin North Am, 2022, 40(3): 565-581.doi: 10.1016/j.emc.2022.05.008 . |
| [2] | DAVIES M G, HART J P. Current status of ECMO for massive pulmonary embolism [J]. Front Cardiovasc Med, 2023, 10: 1298686.doi: 10.3389/fcvm.2023.1298686 . |
| [3] | ABDULAZIZ S M, KALAR V, KUMAR P G, et al. Mechanical Circulatory Support for Massive Pulmonary Embolism [J]. J Am Heart Assoc, 2025, 14(1): e036101. doi: 10.1161/JAHA. 124. 036101 . |
| [4] | ALASAMMANl M, CHOUDHRY A M, ALSAADI A M, et al. Ultrasound-Accelerated Catheter-Directed Thrombolysis [J]. Cardiol Res, 2023, 14(3): 161-166.doi: 10.14740/cr1490 . |
| [5] | 中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组.肺血栓栓塞症诊治与预防指南[J].中华医学杂志, 2018, 98(14):1060-1087.doi:10.3760/cma.j.issn.0376-2491.2018.14.007 . |
| [6] | KHANDAIT H, HARKUT P, KHANDAI V, et al. Acute pulmonary embolism: Diagnosis and management [J]. Indian Heart J, 2023, 75(5): 335-342.doi: 10.1016/j.ihj.2023.05.007 . |
| [7] | MEHRANE R, RAO S V, BHATT D L,et al.Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the BledingAcademic Research Consortium[J]. Circulation,2011,123(23):2736-2747.doi: 10.1161/CIRCULATIONAHA.110.009449 . |
| [8] | KASO E R, PAN J A, SALERNO M, et al. Venoarterial Extracorporeal Membrane Oxygenation for Acute Massive Pulmonary Embolism: A Meta-Analysis and Call to Action [J]. J Cardiovasc Transl Res, 2022, 15(2): 258-267.doi: 10.1007/s12265-021-10158-0 . |
| [9] | VAN LUIJTELAAR A, FUTTERER J J, BOMERS J G. Minimally invasive magnetic resonance image-guided prostate interventions [J]. Br J Radiol, 2022, 95(1131): 20210698. doi: 10.1259/bjr.20210698 . |
| [10] | ROULEAU S G, CACEY S D, KABRHEL C, et al. Management of high-risk pulmonary embolism in the emergency department: A narrative review [J]. Am J Emerg Med, 2024, 79: 1-11.doi: 10.1016/j.ajem.2024.01.039 . |
| [11] | MILLER S E, WARACH S J. Evolving Thrombolytics: from Alteplase to Tenecteplase [J]. Neurotherapeutics, 2023, 20(3):664-678.doi: 10.1007/s13311-023-01391-3 . |
| [12] | LI S, GU H Q, LI H, et al. Reteplase versus Alteplase for Acute Ischemic Stroke [J]. N Engl J Med, 2024, 390(24): 2264-2273.doi: 10.1056/NEJMoa2400314 . |
| [13] | MENG X, LI S, DAI H, et al. Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial [J]. JAMA,2024, 332(17):1437-1445. doi: 10.1001/jama.2024.14721 . |
| [14] | BIKOV A, MESZAROS M, SCHWARZ E I. Coagulation and Fibrinolysis in Obstructive Sleep Apnoea [J]. Int J Mol Sci, 2021, 22(6):2834.doi: 10.3390/ijms22062834 . |
| [15] | MA P, ZHANG Y, CHANG L, et al. Tenecteplase vs. alteplase for the treatment of patients with acute ischemic stroke: A systematic review and meta-analysis [J]. J Neurol,2022, 269(10):5262-5271. doi: 10.1007/s00415-022-11242-4 . |
| [16] | ALIJANIl B, BIJANI E, REIHANIAN Z, et al. Clinical Efficacy of Intraventricular rt-PA (Actilyse(?)) in the Outcome of Patients with Spontaneous Intraventricular Hemorrhage [J]. Turk Neurosurg, 2023, 33(2): 283-289.doi: 10.5137/1019-5149.JTN. 38347-22.3 . |
| [17] | ZHONG K, AN X, KONG Y, et al. Predictive model for the risk of hemorrhagic transformation after rt-PA intravenous thrombolysis in patients with acute ischemic stroke: A systematic review and meta-analysis [J]. Clin Neurol Neurosurg, 2024, 239: 108225. doi: 10.1016/j.clineuro.2024.108225 . |
| [18] | ABUELAZM M, SERI A R, AWAD A K, et al. The efficacy and safety of tenecteplase versus alteplase for acute ischemic stroke: an updated systematic review, pairwise, and network meta-analysis of randomized controlled trials [J]. J Thromb Thrombolysis,2023, 55(2):322-338. doi: 10.1007/s11239-022-02730-5 . |
| [19] | COMCORS S J, KATZ M H G, IKOMA N. Minimally Invasive Pancreatectomy: Robotic and Laparoscopic Developments [J]. Surg Oncol Clin N Am, 2023, 32(2): 327-342.doi: 10.1016/j.soc.2022.10.009 . |
| [20] | WANG L, HAO M, WU N, et al. Comprehensive Review of Tenecteplase for Thrombolysis in Acute Ischemic Stroke [J]. J Am Heart Assoc, 2024, 13(9): e031692.doi: 10.1161/JAHA. 123. 031692 . |
| [21] | 张昌志,陶禹至,余倩,等.急性肺栓塞不同预后评分的临床效能评价分析[J].实用医学杂志,2024,40(3):336-342.doi:10.3969/j.issn.1006-5725.2024.03.010 . |
| [22] | 郭润财,王蕾,黄振国,等.基于从头训练模式深度学习卷积神经网络模型评估急性肺栓塞的价值[J].实用医学杂志,2023,39(22):2979-2983.doi:10.3969/j.issn.1006-5725.2023.22.021 . |
| [23] | JABER W A, GONSALVES C F, STORTECKY S,et al. Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial[J]. Circulation,2025,151(5):260-273.doi: 10.1161/CIRCULATIONAHA.124.072364 . |
| [24] | HAAMMACHE M, SIMARD C, HAMEL S,et al. Diagnosing Pulmonary Embolism During Pregnancy[J] .Chest, 2025, 168(4): 1007-1017.doi: 10.1016/j.chest.2025.05.014 . |
| [25] | STADLBAUER A, VERBELEN T, BINZENHOFER L,et al. Management of high-risk acute pulmonary embolism: An emulated target trial analysis[J]. Intensive Care Med,2025,51(3):490-505.doi: 10.1007/s00134-025-07805-4 . |
/
| 〈 |
|
〉 |